NCT07445984Recruiting
Chemogenomic Profiling in Hematological Malignancies (HEM-Profiling 2021)
Source: ClinicalTrials.gov · Last updated 3 Mar 2026
Brief summary (registry, in English)
The study will be conducted retrospectively and prospectively, using bone marrow (BM) or peripheral blood (PB) samples or biopsies of lymph nodes or tissues with metastatic involvement taken from previously stored samples here at the University Hospital of Parma or taken from patients that need to underwent diagnostic evaluation for a suspect or a defined diagnosis of hematological malignancies collected at the University Hospital of Parma.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 250 (estimated)
- First submitted
- 13 Feb 2026
- Start date
- 28 Jul 2021
- Primary completion date
- 28 Jul 2026
- Lead sponsor
- Azienda Ospedaliero-Universitaria di Parma
- NCT number
- NCT07445984
What you commit to
- Study type: Interventional
- Planned participants: 250
- From 28 Jul 2021 to the primary completion date, 28 Jul 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who are unable to provide informed consent prior to any procedure for any reason.
Age
- Age \<1 year old
Who the study is looking for
- Patient aged \>1 year old, referred for evaluation to the University Hospital of Parma;
- Retrospective study: previously patients with hematological malignancies;
- Prospective study: 1) patients with clinical suspect of hematological malignancies which requires a diagnostic assessment using peripheral blood drawn, bone marrow aspirate/biopsy, lymph nodes biopsies or biopsies of tissues with metastatic involvement including liquor from rachicentesis, tissue aspirate etc. 2) patients with clinical suspect of relapsed/refractory onco-hematological disorder, which requires a diagnostic assessment using bone marrow aspirate/biopsy or biopsies of tissues with metastatic involvement including lymph nodes, liquor from rachicentesis, tissue aspirate etc. 3) patients that progress in blastic transformation from a chronic condition or suspect of relapsed/refractory hematological disease, which requires a diagnostic assessment using peripheral blood drawn, bone marrow aspirate/biopsy, lymph nodes biopsies or biopsies of tissues with metastatic involvement including liquor from rachicentesis, tissue aspirate etc;
- Written informed consent. Retrospective study: informed consent will be signed during the first follow-up visit.
Age in the registry: 1 year to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Parma Coordinator of this site? Confirm its status | Parma | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.